Industry News
Flipping the switch to better see cancer cells at depths
11/10/2015
Using a high-tech imaging method, a team of biomedical engineers at the School of Engineering & Applied Science at Washington University in St.
New genetic cause of a childhood kidney cancer discovered
11/09/2015
Genetic mutations in a gene called REST have been shown to cause Wilms tumour, a rare kidney cancer that occurs in children.
International experts have called for a clinical trial to investigate the best ways for identifying and treating a small but important group of patients with advanced breast cancer who can survive...
Will avoiding meat reduce risk of kidney cancer?
11/09/2015
Eating meat cooked at high temperatures appears to increase the chance of kidney cancer, especially when combined with genetic factors.
MD Anderson study also finds individuals with certain genetic variations more vulnerable to dietary risk.
PharmaMar's novel ADC demonstrates anticancer activity in HER2-expressing
11/09/2015
PharmaMar (MSE:PHM), a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs, has announced that its novel Antibody-Drug Conjugate...
World first blood test reduces risk and increases accuracy in prenatal testing
11/09/2015
Research into a simple, accurate and low risk blood test that can detect foetal blood group, sex, and genetic conditions in unborn babies has been published in the international scientific journal...
Targeted treatment produces rapid shrinkage of recurrent, BRAF-mutant brain tumor
11/09/2015
BRAF inhibition stops regrowth of debilitating craniopharyngioma, suggests new treatment options.
Cancer survivors less likely to receive callbacks from potential employers
11/09/2015
Job applicants who are cancer survivors are less likely to receive callbacks from potential retail employers than those who did not disclose their health history, according to a recent study by Rice...
New, investigational PARP1/2 inhibitor BGB-290 shows promise against ovarian cancer
11/08/2015
Treatment with BGB-290, a new, investigational, highly selective inhibitor ofPARP1/2, was safe, tolerable, and yielded clinical responses in patients with advanced ovariancancer, according to...